Mediwound Ltd
mediwound.comWhat Do They Do?
Sells NexoBrid, an enzyme-based treatment that removes dead tissue from severe burns, to burn centers and hospital burn units, and develops enzymatic treatments for chronic wounds and a topical treatment for basal cell carcinoma.
20-F for FY2025, filed Mar 5, 2026Our flagship product, NexoBrid, is a topically administered biological orphan drug that enzymatically removes eschar while preserving…View ↗
EscharEx® is a bromelain-based, bioactive enzymatic therapy in advanced clinical development for the debridement of chronic and…View ↗
Our pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in…View ↗
The Company generates revenues from sales of its innovative biopharmaceutical product, Nexobrid, to burn centers and hospital burn units in…View ↗
Who Are Their Customers?
Burn centers and hospital burn units receive NexoBrid through the company’s commercial organizations and local distributors. The company has local distribution agreements across Europe, Asia-Pacific and the Middle East.
20-F for FY2025, filed Mar 5, 2026
Do Revenues Turn Into Profits?
No. It lost $23.9M in .
20-F for FY2025, filed Mar 5, 2026
Who Do They Compete With?
Competes with Smith & Nephew
20-F for FY2025, filed Mar 5, 2026In addition, we face competition from the current SOC. The current SOC for eschar removal in severe burns is surgery, where eschar removal…View ↗
Loading...
